EU concludes talks on potential COVID-19 vaccine supply from J&J

Cornelia Mascio
Agosto 15, 2020

Britain will buy potential COVID-19 vaccines from US drugmakers Johnson & Johnson and Novavax Inc, the companies said on Friday, bringing the total number of deals by the United Kingdom government to six as the race for shots heats up.

The deals include an initial 60 million doses of Novavax's vaccine and 30 million doses of J&J's vaccine. The Commission now has agreed the basis for a contractual framework for the purchase of 300 million doses of the AstraZeneca vaccine, with an option to purchase 100 million more, on behalf of EU Member States. This study will run in parallel with another phase 3 trial investigating the single-dose regimen of Ad26.COV2.S.

The European Union (EU) reached on Friday its first agreement to purchase a potential vaccine against COVID-19 once it is proven to be safe and effective, the European Commission said in a press release.

Supported by the government, another vaccine development company Novavax will conduct a Phase 3 clinical trial of its vaccine working with Britain's National Institute for Health Research (NIHR) to access their clinical network and expertise.

NVX-CoV2373 has already produced promising phase 1 trial results, after inducing immune responses in participants treated at two doses levels, with and without an adjuvant.

The Biological E. Limited (BE) on Thursday announced that it has entered into an agreement with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical companies of Johnson and amp; Johnson, for the creation and enhancement of manufacturing capacities for drug substance and drug product for the latter's COVID-19 vaccine candidate.

Friday's announcement follows earlier ones that confirmed the conclusion of exploratory talks for vaccines supply with Sanofi-GSK on July 31 and with Johnson & Johnson on August 13.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE